A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state.
To examine the efficacy of ziprasidone vs. placebo for the depressive mixed state in patients with bipolar disorder type II or major depressive disorder (MDD).73 patients were randomized in a double-blinded, placebo-controlled study to ziprasidone (40-160 mg/d) or placebo for 6 weeks. They met DSM-I...
Main Authors: | Ashwin Patkar, William Gilmer, Chi-un Pae, Paul A Vöhringer, Michael Ziffra, Edward Pirok, Molly Mulligan, Megan M Filkowski, Elizabeth A Whitham, Niki S Holtzman, Sairah B Thommi, Tanya Logvinenko, Antony Loebel, Prakash Masand, S Nassir Ghaemi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3335844?pdf=render |
Similar Items
-
Mania associated with ziprasidone initiation
by: Savvidou Kleopatra, et al.
Published: (2006-02-01) -
Ziprasidone in the Treatment of Delusional Parasitosis
by: P. Contreras-Ferrer, et al.
Published: (2012-07-01) -
A new simple and rapid validated RP-HPLC method for determination of ziprasidone in ziprasidone capsules
by: Ruchi Bansal, et al.
Published: (2016-09-01) -
Spectrophotometric Determination of Ziprasidone in Pharmaceutical Formulations
by: G. Srinubabu, et al.
Published: (2006-01-01) -
Ziprasidone in the treatment of mania in bipolar disorder
by: Stephen E Nicolson, et al.
Published: (2007-01-01)